Drug Profile
Lufepirsen - OcuNexus Therapeutics
Alternative Names: Antisense deoxynucleotide oligomer - OcuNexus Therapeutics; Antisense oligonucleotide compound - OcuNexus Therapeutics; CODA-001; Connexin43 antisense oligonucleotide - OcuNexus Therapeutics; NexagonLatest Information Update: 08 Aug 2023
Price :
$50
*
At a glance
- Originator CoDa Therapeutics (NZ); CoDa Therapeutics Inc
- Developer CoDa Therapeutics Inc; Eyevance Pharmaceuticals; OcuNexus Therapeutics
- Class Antisense oligonucleotides; Antiulcers; Eye disorder therapies; Foot disorder therapies; Skin disorder therapies
- Mechanism of Action Connexin 43 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Corneal injuries
- No development reported Diabetic foot ulcer; Leg ulcer; Wounds
Most Recent Events
- 31 Jul 2023 Phase-II/III clinical trials in Corneal injuries (In adolescents, In children, In the elderly, In adults) in USA (Opthalmic) (NCT05966493)
- 26 Sep 2022 Lufepirsen is still in phase II trial for Corneal injuries (In adolescents, In children, In the elderly, In adults) in India, USA (Topical) (NCT04081103) (CTRI2019-08-020943)
- 12 Jan 2022 Amber Ophthalmics has patent protection for lufepirsen (Amber Ophthalmics website, January 2022)